Combination of Trabectedin and Gemcitabine for Advanced Soft Tissue Sarcomas: Results of a Phase I Dose Escalating Trial of the German Interdisciplinary Sarcoma Group (GISG)

Background: Evaluation of the potential efficacy and safety of combination therapies for advanced soft tissue sarcomas (STS) has increased substantially after approval of trabectedin and pazopanib. Trabectedin’s introduction in Europe in 2007 depended mainly on its activity in so-called L-sarcomas (...

Descripción completa

Detalles Bibliográficos
Autores principales: Kasper, Bernd, Reichardt, Peter, Pink, Daniel, Sommer, Michaela, Mathew, Monika, Rauch, Geraldine, Hohenberger, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4306943/
https://www.ncbi.nlm.nih.gov/pubmed/25591040
http://dx.doi.org/10.3390/md13010379

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4306943/
https://www.ncbi.nlm.nih.gov/pubmed/25591040
http://dx.doi.org/10.3390/md13010379

Ejemplares similares